Aether Industries (AETHER) investor relations material

Executive summary

• Q1 FY27 began in line with expectations, with consolidated revenue rising 27% year-over-year to ₹3,266M, driven by strong growth in CEM and CRAMS, which now contribute 60% of revenue and are targeted to reach 70% in two years.

• EBITDA increased 31% year-over-year to ₹1,028M, with margin expansion due to a strategic shift toward higher-margin segments.

• PAT grew 33% year-over-year to ₹627M, reflecting improved segment mix and operational efficiency.

• Commercial production commenced at new facilities (Site 3++ and Site 5), and 10 new customers were onboarded, with over nine customer and certification audits completed.

• Landmark R&D partnership with Dow Chemical for silicone technology and entry into the semiconductor supply chain position the company for future growth.

Financial highlights

• Q1 FY27 consolidated revenue rose to ₹3,266M, up from ₹2,566M in Q1 FY26.

• EBITDA was ₹1,028M, up from ₹785M in Q1 FY26, with margin at 31% (up from 30%).

• PAT reached ₹627M, up from ₹470M in Q1 FY26, with PAT margin at 19% (up from 18%).

• Gross margin improved to 49.83% in Q1 FY27 from 47.93% in Q1 FY26.

• CapEx for Q1 FY27 was ₹943M; full-year CapEx expected at ₹3,000–3,500M, mainly for Site 5 and new R&D.

Outlook and guidance

• CEM and CRAMS are expected to drive 70%+ of revenue in the next few years, with continued margin expansion and EBITDA margin guidance at approximately 30% for FY27.

• The company targets 25%-30% compounding growth in core specialty and CRAMS plus CEM business.

• Magnum (Site 5) Phase I is online; Phase II expected by FY2030, with strong pre-audit demand.

• R&D expansion and new product launches in oil & gas and material science are planned for upcoming quarters.

• New LSM products from Magnum to contribute from Q2 FY27; strong visibility for further production block ramp-up.